Zhitong Finance App News, Fuyuan Pharmaceutical (601089.SH) issued an announcement. Recently, the company received an “Drug Registration Certificate” for upatinib extended-release tablets [specification: 15 mg (measured according to CHF N O)] issued by the State Drug Administration to approve the production of the drug.

According to reports, this drug is used for atopic dermatitis, rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, Crohn's disease, radiology-negative axial spondylitis (NR-axSPA), ankylosing spondylitis (AS, radiology-positive axial spondylitis), and giant cell arteritis. According to relevant national policies and regulations, obtaining a “Drug Registration Certificate” this time is considered to have passed the consistency evaluation.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.